1 / 21

Special Topics in IND Regulation

Special Topics in IND Regulation. David Roeder, M.S. Associate Director for Regulatory Affairs Office of Drug Evaluation IV Center for Drugs, FDA April 14, 2005. Special Topics in IND Regulation. When Is an IND Needed? Clinical Holds Data Monitoring Committees (DMCs).

nowles
Download Presentation

Special Topics in IND Regulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Special Topics in IND Regulation David Roeder, M.S. Associate Director for Regulatory Affairs Office of Drug Evaluation IV Center for Drugs, FDA April 14, 2005

  2. Special Topics in IND Regulation • When Is an IND Needed? • Clinical Holds • Data Monitoring Committees (DMCs)

  3. When is an IND Needed? Questions to ask • Is it a drug? • Is it being used in a clinical investigation? • Is it a drug that is lawfully marketed in the U.S. for another use?

  4. Is it a Drug? • “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease…” and • “articles (other than food) intended to affect the structure or any function of the body…” (21 USC 321(g)(1)(B) and (C)) • The second prong of the definition does not apply to dietary supplements • Note that a drug is defined by intended use, not the nature of the substance

  5. Is it a Clinical Investigation? • A “clinical investigation” is “any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects.” • An “experiment” is “any use of a drug except for the use of a marketed drug in the course of medical practice.” • Not limited to commercial development

  6. Is it a Drug that is Lawfully Marketed in the U.S. for Another Use? • 21 CFR 312.2 provides for exemptions for certain clinical studies of approved drugs for unapproved uses • Most cases can be determined by the sponsor or investigator • An exemption letter from the FDA is generally not necessary • When in doubt, consult with the FDA

  7. IND Exemptions for Lawfully Marketed Drug Products(must meet all criteria) • Study is not intended to be reported as a well-controlled study for a new indication or significant labeling change • Study is not intended to support significant change in advertising • Does not involve a route of administration, dosing level, or patient population that significantly increases the risk (or decreases the acceptability of risk)

  8. IND Exemptions for Lawfully Marketed Drug Products (cont.) • Conducted in compliance with 21 CFR 56 (IRB) and 21 CFR 50 (informed consent) • Conducted in compliance with 21 CFR 312.7 (promotion and charging)

  9. Other IND Exemptions • Certain studies with in vitro biologic diagnostic products • Blood grouping serum • Reagent red blood cells • Anti-human globulin • In vitro or laboratory research animals • Certain bioavailability studies • Radioactive drugs for certain research uses

  10. Difficult Cases • “Provocation” or “challenge” studies • Stable isotopes • “Shelf chemicals” • Drug vs. nutritional supplement • Foreign studies

  11. Clinical Holds

  12. Clinical Holds • Study cannot proceed until 30 days from FDA receipt (new INDs only) • Can be imposed at any time subsequent to 30-day safety review • Unless accompanied by a clinical hold, agency comments are advisory only • Partial clinical hold vs. full clinical hold

  13. Grounds for Imposing a Clinical Hold: Phase 1 • Human subjects at unreasonable and significant risk • Unqualified investigator(s) • Investigator brochure misleading, erroneous or incomplete • Insufficient information to assess risk • Exclusion by gender if for life-threatening condition

  14. Grounds for Imposing a Clinical Hold: Phase 2 or 3 • Any reason cited in previous slide • Protocol deficient in design to meet stated objective

  15. Grounds for Imposing a Clinical Hold: Other • Treatment IND or protocol • Certain studies that are not designed to be adequate and well-controlled • Certain investigations involving exception from informed consent

  16. Data Monitoring Committees (DMCs)

  17. FDA Guidance • Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees (draft guidance) November 2001 • Final guidance pending

  18. Regulatory Requirements • Requirement for sponsor to monitor progress of clinical trials [21 CFR 312.56] can be partly addressed with DMC • DMC required if exception from informed consent for emergency research [21 CFR 50.24(a)(7)(iv)] • Otherwise, no requirement for DMC

  19. Considerations for Assessing the Need for a DMC • Risk to trial participants • Practicality of DMC review • Short-term trials normally not practical • If DMC is used for short-term study, “pauses” can be incorporated • Assurance of scientific validity

  20. Examples of Studies for Which DMCs are Often Recommended • Cardiovascular trials with morbidity/mortality endpoints • HIV, HBV, sepsis trials • Some rare and unpredictable serious infections (e.g., draft guidance for vaccinia complications)

  21. Special Considerations • DMC models based on federally funded trials are acceptable • DMC should be multidisciplinary • DMC members should be free of conflict of interest

More Related